C8 Galactosylceramide (d18:1/8:0) – 10 mg

Brand:
Cayman
CAS:
41613-16-5
Storage:
-20
UN-No:
Non-Hazardous - /

C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids.{37368} It increases the amount delivered and toxicity of doxorubicin (Item No. 15007) in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo.{37369} It also activates NF-κB production in C6 glioma cells when used at a concentration of 10 μM.{38647} [Matreya, LLC. Catalog No. 1334]  

 

Available on backorder

SKU: 24346 - 10 mg Category:

Description

A synthetic bioactive sphingolipid; increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated in the nanoliposomal membrane of nanoliposomal-doxorubicin; induces proliferation and cytokine production by splenocytes in vitro (100-1,000 ng/ml); activates NF-κB production in C6 glioma cells (10 μM)


Formal name: N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-octanamide

Synonyms:  Galactosylceramide (d18:1/8:0)|GalCer(d18:1/8:0)|N-octanoyl-β-D-Galactosylceramide

Molecular weight: 587.8

CAS: 41613-16-5

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cancer||Research Area|Cell Biology|Cell Signaling|NF-κB Signaling||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors||Research Area|Immunology & Inflammation||Research Area|Lipid Biochemistry|Sphingolipids